These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. O'Meara E; McDonald M; Chan M; Ducharme A; Ezekowitz JA; Giannetti N; Grzeslo A; Heckman GA; Howlett JG; Koshman SL; Lepage S; Mielniczuk LM; Moe GW; Swiggum E; Toma M; Virani SA; Zieroth S; De S; Matteau S; Parent MC; Asgar AW; Cohen G; Fine N; Davis M; Verma S; Cherney D; Abrams H; Al-Hesayen A; Cohen-Solal A; D'Astous M; Delgado DH; Desplantie O; Estrella-Holder E; Green L; Haddad H; Harkness K; Hernandez AF; Kouz S; LeBlanc MH; Lee D; Masoudi FA; McKelvie RS; Rajda M; Ross HJ; Sussex B Can J Cardiol; 2020 Feb; 36(2):159-169. PubMed ID: 32036861 [TBL] [Abstract][Full Text] [Related]
5. Assessment of clinical characteristics of cardiac amyloidosis as a potential underlying etiology in patients diagnosed with heart failure with preserved ejection fraction. Murat S; Cavusoglu Y; Yalvac HE; Sivrikoz IA; Kocagil S Kardiol Pol; 2022; 80(6):672-678. PubMed ID: 35390167 [TBL] [Abstract][Full Text] [Related]
6. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD; J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936 [TBL] [Abstract][Full Text] [Related]
8. Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial. Vaduganathan M; Cunningham JW; Claggett BL; Causland FM; Barkoudah E; Finn P; Zannad F; Pfeffer MA; Rizkala AR; Sabarwal S; McMurray JJV; Solomon S; Desai AS JACC Heart Fail; 2021 May; 9(5):374-382. PubMed ID: 33839075 [TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633 [TBL] [Abstract][Full Text] [Related]
10. Endomyocardial Biopsy Characterization of Heart Failure With Preserved Ejection Fraction and Prevalence of Cardiac Amyloidosis. Hahn VS; Yanek LR; Vaishnav J; Ying W; Vaidya D; Lee YZJ; Riley SJ; Subramanya V; Brown EE; Hopkins CD; Ononogbu S; Perzel Mandell K; Halushka MK; Steenbergen C; Rosenberg AZ; Tedford RJ; Judge DP; Shah SJ; Russell SD; Kass DA; Sharma K JACC Heart Fail; 2020 Sep; 8(9):712-724. PubMed ID: 32653448 [TBL] [Abstract][Full Text] [Related]
11. Assessing the Eligibility Criteria in Phase III Randomized Controlled Trials of Drug Therapy in Heart Failure With Preserved Ejection Fraction: The Critical Play-Off Between a "Pure" Patient Phenotype and the Generalizability of Trial Findings. Patel HC; Hayward C; Dungu JN; Papadopoulou S; Saidmeerasah A; Ray R; Di Mario C; Shanmugam N; Cowie MR; Anderson LJ J Card Fail; 2017 Jul; 23(7):517-524. PubMed ID: 28434933 [TBL] [Abstract][Full Text] [Related]
12. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. Lund LH; Savarese G; Venkateshvaran A; Benson L; Lundberg A; Donal E; Daubert JC; Oger E; Linde C; Hage C ESC Heart Fail; 2022 Feb; 9(1):164-177. PubMed ID: 34811954 [TBL] [Abstract][Full Text] [Related]
13. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076 [TBL] [Abstract][Full Text] [Related]
14. Incidence and Outcomes of Pneumonia in Patients With Heart Failure. Shen L; Jhund PS; Anand IS; Bhatt AS; Desai AS; Maggioni AP; Martinez FA; Pfeffer MA; Rizkala AR; Rouleau JL; Swedberg K; Vaduganathan M; Vardeny O; van Veldhuisen DJ; Zannad F; Zile MR; Packer M; Solomon SD; McMurray JJV J Am Coll Cardiol; 2021 Apr; 77(16):1961-1973. PubMed ID: 33888245 [TBL] [Abstract][Full Text] [Related]
15. Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. Jering K; Claggett B; Redfield MM; Shah SJ; Anand IS; Martinez F; Sabarwal SV; Seferović PM; Kerr Saraiva JF; Katova T; Lefkowitz MP; Pfeffer MA; McMurray JJV; Solomon SD JACC Heart Fail; 2021 May; 9(5):386-397. PubMed ID: 33714741 [TBL] [Abstract][Full Text] [Related]
16. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930 [TBL] [Abstract][Full Text] [Related]
17. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction. Chen W; Ton VK; Dilsizian V Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Wintrich J; Kindermann I; Ukena C; Selejan S; Werner C; Maack C; Laufs U; Tschöpe C; Anker SD; Lam CSP; Voors AA; Böhm M Clin Res Cardiol; 2020 Sep; 109(9):1079-1098. PubMed ID: 32236720 [TBL] [Abstract][Full Text] [Related]
19. Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. Vaduganathan M; Claggett BL; Desai AS; Anker SD; Perrone SV; Janssens S; Milicic D; Arango JL; Packer M; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD J Am Coll Cardiol; 2020 Jan; 75(3):245-254. PubMed ID: 31726194 [TBL] [Abstract][Full Text] [Related]
20. Transthyretin Cardiac Amyloidosis: An Evolution in Diagnosis and Management of an "Old" Disease. Smiley DA; Rodriguez CM; Maurer MS Cardiol Clin; 2022 Nov; 40(4):541-558. PubMed ID: 36210137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]